AdaptHealth Corp
For the period ended Feb 25, 2025. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 25, 2025 · Filed Feb 25, 2025
Contents
EX-99.1 · EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin
EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin
This press release presents AdaptHealth’s EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin for the three and twelve months ended December 31, 2024 and 2023.
AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization, including patient equipment depreciation.
AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus equity-based compensation expense, change in fair value of the warrant liability, goodwill impairment, loss on extinguishment of debt, litigation settlement expense, and certain other non-recurring items of expense or income.
AdaptHealth defines Adjusted EBITDA Margin as Adjusted EBITDA (as defined above) as a percentage of net revenue.
The following unaudited table presents the reconciliation of net income (loss) attributable to AdaptHealth Corp., to EBITDA and Adjusted EBITDA, and the reconciliation of net income (loss) attributable to AdaptHealth Corp. as a percentage of net revenue to Adjusted EBITDA Margin, for the three months December 31, 2024 and 2023:
| Three Months Ended December 31, | |||||
|---|---|---|---|---|---|
| 2024 · 2023 | |||||
| (Unaudited) | |||||
| (in thousands, except percentages) · Dollars · Revenue Percentage · Dollars · Revenue Percentage | |||||
| Net income (loss) attributable to AdaptHealth Corp. | $50,262 | 5.9% | $(254,503) | (29.7)% | |
| Income attributable to noncontrolling interest | 1,141 | 0.1% | 928 | 0.1% | |
| Interest expense, net | 29,729 | 3.5% | 33,486 | 3.9% | |
| Income tax expense (benefit) | 19,308 | 2.3% | (18,111) | (2.1)% | |
| Depreciation and amortization, including patient equipment depreciation | 90,537 | 10.6% | 92,364 | 10.8% | |
| EBITDA | 190,977 | 22.4% | (145,836) | (17.0)% | |
| Equity-based compensation expense (a) | 4,266 | 0.5% | 5,184 | 0.6% | |
| Change in fair value of warrant liability (b) | (2,221) | (0.3)% | (2,596) | (0.3)% | |
| Goodwill impairment (c) | — | —% | 318,921 | 37.2% | |
| Litigation settlement expense (d) | — | —% | 25,140 | 2.9% | |
| Other non-recurring expenses, net (e) | 7,578 | 0.8% | 3,806 | 0.4% | |
| Adjusted EBITDA | $200,600 | 23.4% | $204,619 | 23.8% | |
| Adjusted EBITDA Margin | 23.4% | 23.8% | |||
-8 -
| (a) | Represents equity-based compensation expense for awards granted to employees and non-employee directors. |
| (b) | Represents non-cash gains for the changes in the estimated fair value of the warrant liability. The warrants expired on November 8, 2024. |
| (c) | The 2023 period includes non-cash goodwill impairment charges as a result of the fair value of the Company’s reporting unit at that time being less than it's carrying value. |
| (d) | The 2023 period includes a charge relating to a previously disclosed securities class action lawsuit, net of contributions from the Company’s insurers. |
| (e) | The 2024 period consists of $4.2 million of consulting expenses associated with systems implementation activities, $1.6 million of consulting expenses associated with asset dispositions, $1.0 million of expenses associated with litigation, $0.5 million of severance charges, and $0.3 million of other non-recurring expenses. The 2023 period consists of $1.7 million of consulting expenses associated with systems implementation activities, $1.4 million of expenses associated with litigation, $0.8 million of severance charges, $0.6 million of lease termination costs associated with a cost management program, $0.3 million of transaction costs, and $1.5 million of other non-recurring expenses, offset by income of $2.5 million related to changes in AdaptHealth's estimated liability related to its Tax Receivable Agreement. |
The following unaudited table presents the reconciliation of net income (loss) attributable to AdaptHealth Corp., to EBITDA and Adjusted EBITDA, and the reconciliation of net income (loss) attributable to AdaptHealth Corp. as a percentage of net revenue to Adjusted EBITDA Margin, for the twelve months ended December 31, 2024 and 2023:
| Twelve Months Ended December 31, | |||||
|---|---|---|---|---|---|
| 2024 · 2023 | |||||
| (Unaudited) | |||||
| (in thousands, except percentages) · Dollars · Revenue Percentage · Dollars · Revenue Percentage | |||||
| Net income (loss) attributable to AdaptHealth Corp. | $90,422 | 2.8% | $(678,895) | (21.2)% | |
| Income attributable to noncontrolling interest | 4,358 | 0.1% | 4,115 | 0.1% | |
| Interest expense, net | 126,668 | 3.9% | 130,299 | 4.1% | |
| Income tax expense (benefit) | 41,239 | 1.3% | (49,004) | (1.5)% | |
| Depreciation and amortization, including patient equipment depreciation | 365,334 | 11.1% | 382,783 | 12.0% | |
| EBITDA | 628,021 | 19.2% | (210,702) | (6.5)% | |
| Equity-based compensation expense (a) | 14,880 | 0.5% | 22,468 | 0.7% | |
| Change in fair value of warrant liability (b) | (4,021) | (0.1)% | (34,482) | (1.1)% | |
| Goodwill impairment (c) | 13,078 | 0.4% | 830,787 | 26.0% | |
| Loss on extinguishment of debt (d) | 2,273 | 0.1% | — | —% | |
| Litigation settlement expense (e) | 3,338 | 0.1% | 25,140 | 0.8% | |
| Other non-recurring expenses, net (f) | 31,088 | 0.9% | 37,584 | 1.1% | |
| Adjusted EBITDA | $688,657 | 21.1% | $670,795 | 21.0% | |
| Adjusted EBITDA Margin | 21.1% | 21.0% | |||
-9 -
| (a) | Represents equity-based compensation expense for awards granted to employees and non-employee directors. |
| (b) | Represents non-cash gains for the changes in the estimated fair value of the warrant liability. The warrants expired on November 8, 2024. |
| (c) | The 2024 period includes non-cash goodwill impairment charges relating to the disposition of certain immaterial custom rehab technology assets. The 2023 period includes non-cash goodwill impairment charges as a result of the fair value of the Company’s reporting unit at that time being less than it's carrying value. |
| (d) | Represents lender fees and the write-off of unamortized deferred financing costs in connection with the refinancing of the Company's credit agreement. |
| (e) | The 2024 period includes a $2.4 million charge for the change in fair value of the shares of Common Stock of the Company that were issued in July 2024 following final court approval of a previously disclosed securities class action lawsuit, as well as an expense of $0.9 million to settle a shareholder derivative complaint. The 2023 period includes a charge relating to a previously disclosed securities class action lawsuit, net of contributions from the Company’s insurers. |
| (f) | The 2024 period consists of $13.9 million of consulting expenses associated with systems implementation activities, $4.5 million of consulting expenses associated with asset dispositions, $4.2 million of expenses associated with litigation, $3.9 million of severance charges (primarily related to the separation of the Company's former President), $2.7 million write-down of assets, and $1.9 million of other non-recurring expenses. The 2023 period consists of $13.9 million of expenses associated with litigation, $7.1 million of severance charges (of which $2.9 million relates to the separation of the Company's former CEO), $5.6 million of consulting expenses associated with systems implementation activities, $5.2 million of consulting expenses associated with cost savings initiatives, $4.8 million of lease termination costs associated with a cost management program, $1.0 million of transaction costs and expenses related to integration efforts related to acquisitions, $0.9 million of net impairments of operating lease right-of-use assets as a result of vacating the leased facilities, and $1.6 million of other non-recurring expenses, offset by income of $2.5 million related to changes in AdaptHealth's estimated liability related to its Tax Receivable Agreement. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.